Browse the evidence

A maladaptive adipokine milieu is associated with endothelial dysfunction, myocardial stiffening, and muscle atrophy in HFpEF.

Recognizing this cycle can inform targeted interventions.

Small molecule agonists of GLP-1 receptor have advantages of low cost and oral administration compared to peptide drugs.

Practitioners may consider small molecule GLP-1 receptor agonists as a cost-effective and convenient treatment option.

Higher Genetic Risk Score (GRS) relates to smaller year one change in waist circumference adjusted for body mass index (WCadjBMI) in lifestyle intervention arms.

Practitioners should consider genetic risk factors when designing weight loss interventions, as they may influence outcomes.

Each weighted risk allele in the GRS contributes to a 0.06 cm higher waist circumference at year 1 for individuals with an initial BMI of 34 and a year 1 reduction in BMI of 2.5.

Understanding the genetic contribution to waist circumference can help tailor interventions for individuals.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Emerging mechanisms of obesity-related vascular dysfunction include skeletal muscle inflammation and signals from the gut microbiome.

Practitioners should consider these emerging mechanisms when developing treatment strategies for obesity-related vascular issues.

Recent progress in glucose-responsive systems enables real-time, glucose-triggered therapeutic activation.

This technology could lead to more effective and responsive diabetes treatments.

Recent advancements in anti-obesity drugs allow for genotype-informed treatment options.

Practitioners can utilize genetic information to tailor obesity treatments.

One standard deviation higher polygenic score (PS) related to smaller one-year change in waist circumference adjusted for body mass index (WCadjBMI) in the lifestyle intervention arms at year 1, predicting poorer response among White participants overall.

Practitioners should consider genetic factors when assessing weight loss responses to lifestyle interventions.

Participants assigned a plant-based diet for phase 1 did not see an increase in TMAO during their subsequent animal-meat phase.

Dietary sequencing may influence TMAO levels and cardiovascular risk.

Around 50 significant metabolites and 12 significant microbiota genera correlated with TMAO.

Understanding these correlations may help in developing targeted therapies for CVD prevention.

Adipositas is influenced by environmental factors and genetic variants.

Understanding the dual influence of genetics and environment can guide obesity treatment strategies.

Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.

The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.

Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.

Practitioners may explore the use of dual agonists for enhanced metabolic outcomes in patients.

Tirzepatide improves β-cell function in T2D patients by reprogramming stressed β cells and restoring β-cell identity through FOXO1-dependent transcriptional reactivation.

Practitioners may consider tirzepatide as a therapeutic option for improving β-cell function in T2D patients.

Emerging therapeutic approaches aim to engage multiple bioenergetic pathways to restore metabolic equilibrium.

Practitioners should consider multi-target approaches in developing treatments for metabolic dysfunction.

ALOXE3 is activated during fasting and enhances insulin sensitivity via hepatic PPARγ.

Targeting ALOXE3 may be a viable strategy for improving insulin sensitivity in metabolic diseases.

Insulin resistance (IR) is a cardinal feature of type 2 diabetes mellitus (T2DM) and contributes to elevated cardiovascular disease (CVD) risk.

Addressing insulin resistance is crucial in managing T2DM and reducing CVD risk.

Pharmacological interventions may attenuate the metabolic and inflammatory changes seen in EAT.

These pharmacological options may be considered in managing EAT-related cardiac dysfunction.

The gut microbiome may contribute to the development of obesity in humans.

Practitioners should consider the gut microbiome as a potential factor in obesity management.

The decision tree yields an AUC of 0.898 for phenotyping PCOS.

Clinicians can utilize this decision tree for effective phenotyping of PCOS.

The decision tree aims to improve PCOS management by reducing multiple blood tests and physician workload.

This decision tree could streamline the diagnostic process for PCOS, making it more efficient for healthcare providers.

Consumption of cherries may help to attenuate pain and decrease blood concentrations of biomarkers linked to skeletal muscle degradation.

Incorporating cherries into the diet may benefit individuals looking to reduce muscle degradation and pain.

Cherry anthocyanins may represent a potential non-pharmacological remedy for cardiometabolic diseases.

Cherries may be recommended as a dietary addition for managing cardiometabolic health.